Inspire Medical Systems (NYSE:INSP) Announces FY 2026 Earnings Guidance

Key Points

• Inspire Medical Systems issued FY 2026 guidance for EPS of $1.20–$1.40 and revenue of $850 million–$860 million, broadly in line with analyst expectations of $1.25 EPS and $853.6 million in revenue.
• The company’s latest quarter beat consensus estimates, with EPS of $0.14 and revenue of $206.7 million, but revenue declined 7.9% year over year and EPS fell from $0.38, reflecting ongoing reimbursement and utilization pressures.
• Analyst sentiment remains cautious: the stock has a consensus “Hold” rating and an average price target of $71.24, while management’s comments suggested a possible reimbursement recovery that could support future procedure volumes.

Inspire Medical Systems (NYSE:INSP - Get Free Report) updated its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 1.200-1.400 for the period, compared to the consensus earnings per share estimate of 1.250. The company issued revenue guidance of $850.0 million-$860.0 million, compared to the consensus revenue estimate of $853.6 million.

Inspire Medical Systems Stock Down 0.9%

NYSE INSP opened at $67.52 on Tuesday. Inspire Medical Systems has a twelve month low of $38.91 and a twelve month high of $147.03. The company has a market cap of $1.95 billion, a price-to-earnings ratio of 31.26, a price-to-earnings-growth ratio of 5.37 and a beta of 0.73. The business's fifty day moving average is $68.69 and its 200 day moving average is $58.82.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last issued its quarterly earnings data on Monday, November 2nd. The company reported $0.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.05. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%. The business had revenue of $206.69 million for the quarter, compared to analyst estimates of $204.31 million. During the same quarter in the previous year, the company posted $0.38 EPS. Inspire Medical Systems's quarterly revenue was down 7.9% compared to the same quarter last year. On average, research analysts anticipate that Inspire Medical Systems will post 1.24 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Robert W. Baird boosted their price target on Inspire Medical Systems from $73.00 to $77.00 and gave the stock a "neutral" rating in a report on Tuesday. Royal Bank Of Canada lifted their target price on shares of Inspire Medical Systems from $60.00 to $75.00 and gave the stock a "sector perform" rating in a research report on Thursday, October 1st. Barclays assumed coverage on shares of Inspire Medical Systems in a research report on Tuesday, October 6th. They issued an "underweight" rating and a $65.00 price target for the company. Piper Sandler raised their price target on shares of Inspire Medical Systems from $60.00 to $70.00 and gave the company a "neutral" rating in a research note on Tuesday. Finally, UBS Group began coverage on shares of Inspire Medical Systems in a report on Tuesday, July 28th. They set a "sell" rating and a $39.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company's stock. Based on data from MarketBeat, Inspire Medical Systems has an average rating of "Hold" and a consensus target price of $71.24.

Insider Transactions at Inspire Medical Systems

In other news, insider Jason Kelly sold 963 shares of the business's stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $59.55, for a total value of $57,346.65. Following the transaction, the insider owned 18,985 shares in the company, valued at approximately $1,130,556.75. The trade was a 4.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.20% of the company's stock.

Key Stories Impacting Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Inspire reported third-quarter revenue of approximately $206.7 million, exceeding the $204.3 million consensus estimate. Adjusted earnings of $0.14 per share also topped published estimates of roughly $0.09–$0.10. Inspire Medical Systems Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Management’s commentary pointed toward a potential recovery in the company’s reimbursement environment, which could support procedure volumes and growth if payer-related pressures ease. Inspire Medical Tops Consensus But Misses the Whisper
• Neutral Sentiment: The earnings call was closely watched by analysts for updates on reimbursement, demand and the company’s path back to sustained growth following recent operating challenges. Inspire Medical Systems Q3 2026 Earnings Call Transcript
• Negative Sentiment: Revenue declined 7.9% from the year-ago quarter, while earnings fell to $0.14 per share from $0.38. The results indicate that reimbursement and utilization headwinds remain material despite the quarterly beat. Inspire Medical Systems Q3 Earnings and Revenues Beat Estimates
• Negative Sentiment: Although INSP exceeded official consensus forecasts, reports indicate it missed higher “whisper” expectations, limiting the positive impact of the headline earnings beat and contributing to the weaker share-price reaction. Inspire Medical Tops Consensus But Misses the Whisper

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc develops and commercializes medical devices for the treatment of obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly narrows or becomes blocked during sleep. The company's primary product is Inspire therapy, an implantable system designed to help keep the airway open by stimulating the hypoglossal nerve, which controls muscles involved in maintaining airway patency.

Inspire therapy is intended for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.